Please login to the form below
FMF
This page shows the latest FMF news and features for those working in and with pharma, biotech and healthcare.
Novartis' Ilaris wins three new FDA approvals
Its label now includes Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TARPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF).
Latest news
-
Novartis wins childhood arthritis indication for Ilaris in EU
FMF) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Both conditions are also classified as rare diseases. .
-
Novartis gets FDA green light for new Ilaris indication
Other uses being assessed include tumour necrosis factor receptor-associated periodic syndrome (TRAPS), colchicine-resistant familial Mediterranean fever (FMF) and hyper IgD syndrome (HIDS), and analysts have suggested that - collectively - the
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
